HIV type 1 antigen-responsive CD4+ T-lymphocytes in exposed yet HIV Type 1 seronegative Ugandans.

PubWeight™: 0.90‹?›

🔗 View Article (PMID 15000700)

Published in AIDS Res Hum Retroviruses on January 01, 2004

Authors

Anthony Kebba1, Pontiano Kaleebu, Jennifer Serwanga, Samantha Rowland, David Yirrell, Robert Downing, Jill Gilmour, Nesrina Imami, Frances Gotch, Jimmy Whitworth

Author Affiliations

1: Medical Research Council's Programme on AIDS in Uganda, UVRI, Entebbe, Uganda.

Associated clinical trials:

Examining Factors That May Influence Resistance to HIV-1 Infection | NCT00351442

Articles by these authors

Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog (2008) 6.07

Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol (2004) 5.86

Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet (2002) 5.80

Risk factors for recent HIV infection in Uganda. JAMA (2008) 4.84

Short-course antiretroviral therapy in primary HIV infection. N Engl J Med (2013) 4.82

Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet (2008) 4.70

Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog (2009) 4.56

Standardization of cytokine flow cytometry assays. BMC Immunol (2005) 4.55

Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet (2004) 4.19

Population-based hematologic and immunologic reference values for a healthy Ugandan population. Clin Diagn Lab Immunol (2004) 3.92

Transmission of human herpesvirus 8 by blood transfusion. N Engl J Med (2006) 3.80

Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet (2006) 3.71

Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health (2007) 3.69

Evaluation of a home-based voluntary counselling and testing intervention in rural Uganda. Health Policy Plan (2005) 3.30

Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol (2006) 3.05

Research capacity. Enabling the genomic revolution in Africa. Science (2014) 3.05

HIV prevalence and incidence are no longer falling in southwest Uganda: evidence from a rural population cohort 1989-2005. AIDS (2008) 3.01

Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92

Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial. BMJ (2011) 2.90

Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis (2002) 2.54

Cotrimoxazole prophylaxis by HIV-infected persons in Uganda reduces morbidity and mortality among HIV-uninfected family members. AIDS (2005) 2.50

Antiretroviral therapy improves renal function among HIV-infected Ugandans. Kidney Int (2008) 2.49

Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703-positive individuals and their transmission recipients. J Exp Med (2009) 2.39

CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa. PLoS One (2009) 2.37

Dysfunction and infection of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1. Blood (2003) 2.35

CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 2.32

miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator. Nat Cell Biol (2010) 2.29

Effect of home-based water chlorination and safe storage on diarrhea among persons with human immunodeficiency virus in Uganda. Am J Trop Med Hyg (2005) 2.12

Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses (2010) 2.05

HIV and mortality of mothers and children: evidence from cohort studies in Uganda, Tanzania, and Malawi. Epidemiology (2005) 2.04

Depression and CD4 cell count among persons with HIV infection in Uganda. AIDS Behav (2006) 2.01

Seasonal pulses of Marburg virus circulation in juvenile Rousettus aegyptiacus bats coincide with periods of increased risk of human infection. PLoS Pathog (2012) 2.00

Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease. J Immunol (2007) 1.96

Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci U S A (2009) 1.95

Cryptosporidiosis and microsporidiosis in ugandan children with persistent diarrhea with and without concurrent infection with the human immunodeficiency virus. Am J Trop Med Hyg (2005) 1.90

Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine (2008) 1.89

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine (2011) 1.88

The natural history of HIV-1 and HIV-2 infections in adults in Africa: a literature review. Bull World Health Organ (2004) 1.76

HIV and syphilis prevalence and associated risk factors among fishing communities of Lake Victoria, Uganda. Sex Transm Infect (2011) 1.75

Proportion of deaths and clinical features in Bundibugyo Ebola virus infection, Uganda. Emerg Infect Dis (2010) 1.75

Severe malnutrition with and without HIV-1 infection in hospitalised children in Kampala, Uganda: differences in clinical features, haematological findings and CD4+ cell counts. Nutr J (2006) 1.74

Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents. Clin Vaccine Immunol (2008) 1.71

In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One (2011) 1.71

Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One (2010) 1.71

Helminth infection is not associated with faster progression of HIV disease in coinfected adults in Uganda. J Infect Dis (2004) 1.67

HIV-1 disease progression and fertility: the incidence of recognized pregnancy and pregnancy outcome in Uganda. AIDS (2004) 1.63

Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine (2006) 1.63

HIV type 1 subtype distribution, multiple infections, sexual networks, and partnership histories in female sex workers in Kampala, Uganda. AIDS Res Hum Retroviruses (2011) 1.63

High HIV incidence and socio-behavioral risk patterns in fishing communities on the shores of Lake Victoria, Uganda. Sex Transm Dis (2012) 1.62

Long-term experience providing antiretroviral drugs in a fee-for-service HIV clinic in Uganda: evidence of extended virologic and CD4+ cell count responses. J Acquir Immune Defic Syndr (2005) 1.59

Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. Int J Epidemiol (2013) 1.57

Hepatitis B infection is highly endemic in Uganda: findings from a national serosurvey. Afr Health Sci (2009) 1.56

Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr (2008) 1.51

Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesis. PLoS Pathog (2012) 1.50

Reemerging Sudan Ebola virus disease in Uganda, 2011. Emerg Infect Dis (2012) 1.47

Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J Virol Methods (2009) 1.46

Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala. AIDS (2011) 1.44

Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. J Infect Dis (2010) 1.43

Association between transfusion with human herpesvirus 8 antibody-positive blood and subsequent mortality. J Infect Dis (2012) 1.42

Hepatitis E epidemic, Uganda. Emerg Infect Dis (2010) 1.41

Identification of HIV-1 infected infants and young children using real-time RT PCR and dried blood spots from Uganda and Cameroon. J Virol Methods (2007) 1.39

Breastfeeding, mother-to-child HIV transmission, and mortality among infants born to HIV-Infected women on highly active antiretroviral therapy in rural Uganda. J Acquir Immune Defic Syndr (2010) 1.38

Outbreak of Marburg hemorrhagic fever among miners in Kamwenge and Ibanda Districts, Uganda, 2007. J Infect Dis (2011) 1.37

Couples at risk: HIV-1 concordance and discordance among sexual partners receiving voluntary counseling and testing in Uganda. J Acquir Immune Defic Syndr (2005) 1.36

Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir. J Infect Dis (2010) 1.36

A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses (2009) 1.35

Toll-like receptor 4 mediates innate immunity to Kaposi sarcoma herpesvirus. Cell Host Microbe (2008) 1.35

Equivalence of ELISpot assays demonstrated between major HIV network laboratories. PLoS One (2010) 1.30

High HIV-1 prevalence, risk behaviours, and willingness to participate in HIV vaccine trials in fishing communities on Lake Victoria, Uganda. J Int AIDS Soc (2013) 1.28

Women who fall by the roadside: gender, sexual risk and alcohol in rural Uganda. Addiction (2006) 1.21

Determinants of early and late mortality among HIV-infected individuals receiving home-based antiretroviral therapy in rural Uganda. J Acquir Immune Defic Syndr (2011) 1.21

Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda. J Acquir Immune Defic Syndr (2007) 1.20

Effect of cotrimoxazole prophylaxis taken by human immunodeficiency virus (HIV)-infected persons on the selection of sulfadoxine-pyrimethamine-resistant malaria parasites among HIV-uninfected household members. Am J Trop Med Hyg (2006) 1.20

Interactions between HIV and malaria in non-pregnant adults: evidence and implications. AIDS (2006) 1.20

A balanced type 1/type 2 response is associated with long-term nonprogressive human immunodeficiency virus type 1 infection. J Virol (2002) 1.19

Switch from inhibitory to activating NKG2 receptor expression in HIV-1 infection: lack of reversion with highly active antiretroviral therapy. AIDS (2005) 1.18

Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology (2012) 1.18

Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy. J Virol (2002) 1.18

Prevalence of nodding syndrome--Uganda, 2012-2013. MMWR Morb Mortal Wkly Rep (2014) 1.18

A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One (2012) 1.17

The Southeast Asian Influenza Clinical Research Network: development and challenges for a new multilateral research endeavor. Antiviral Res (2007) 1.17

Effect of CD4+ T cell count and antiretroviral treatment on two serological HIV incidence assays. AIDS Res Hum Retroviruses (2011) 1.16

Oral contraceptive use induces upregulation of the CCR5 chemokine receptor on CD4(+) T cells in the cervical epithelium of healthy women. J Reprod Immunol (2002) 1.15

Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials. PLoS One (2008) 1.15

Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma--associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr (2002) 1.13

The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis. J Biol Chem (2004) 1.13

Subjective impacts of dental caries and fluorosis in rural Ugandan children. Community Dent Health (2005) 1.13

Disease progression by infecting HIV-1 subtype in a seroconverter cohort in sub-Saharan Africa. AIDS (2013) 1.13

Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. J Clin Invest (2014) 1.12